MedTrace Logo

Study of TDM-180935 in Atopic Dermatitis Patients

NCT06363461 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-04-24

No results posted yet for this study

Summary

Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients

Conditions

Interventions

DRUG

TDM-180935 topical ointment 1.0%

TDM-180935 topical ointment 1.0%

DRUG

TDM-180935 topical ointment 2.0%

TDM-180935 topical ointment 2.0%

DRUG

TDM-180935 topical vehicle ointment 1

TDM-180935 topical vehicle ointment 1

DRUG

TDM-180935 topical vehicle ointment 2

TDM-180935 topical vehicle ointment 2

Sponsors & Collaborators

  • Therapeutics, Inc.

    collaborator INDUSTRY

  • Technoderma Medicines Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel J. Piacquadio, M.D. · Therapeutics Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-13
Primary Completion
2025-03-08
Completion
2025-04-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06363461 on ClinicalTrials.gov